Towarzystwo Funduszy Inwestycyjnych PZU SA’s BioMarin Pharmaceuticals BMRN Stock Holding History

Towarzystwo Funduszy Inwestycyjnych PZU SA’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,051	Closed	-$56.9K	–	684
2025 Q3	$56.9K	Sell	1,051 -650	-38%	-$37.2K	0.01%	385
2025 Q2	$93.5K	Hold	1,701	–	–	0.03%	262
2025 Q1	$120K	Buy	1,701 +30	+2%	+$2.02K	0.04%	204
2024 Q4	$110K	Hold	1,671	–	–	0.04%	195
2024 Q3	$117K	Buy	1,671 +230	+16%	+$19.2K	0.04%	181
2024 Q2	$119K	Sell	1,441 -320	-18%	-$26.6K	0.04%	162
2024 Q1	$154K	Hold	1,761	–	–	0.07%	139
2023 Q4	$170K	Buy	+1,761	New	+$156K	0.08%	108
2021 Q3	$65.5K	Hold	848	–	–	0.08%	105
2021 Q2	$70.8K	Hold	848	–	–	0.08%	106
2021 Q1	$64K	Sell	848 -175	-17%	-$14.3K	0.09%	103
2020 Q4	$89.7K	Buy	+1,023	New	+$81.1K	0.09%	74

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Towarzystwo Funduszy Inwestycyjnych PZU SA's BMRN Position: Q4 2025 in Review

Towarzystwo Funduszy Inwestycyjnych PZU SA sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 1,051 shares — an estimated $56.9K sold.

Towarzystwo Funduszy Inwestycyjnych PZU SA first reported a position in BMRN in Q4 2020 and held it in 12 quarters. The position peaked at $170K in Q4 2023. 539 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Towarzystwo Funduszy Inwestycyjnych PZU SA reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Towarzystwo Funduszy Inwestycyjnych PZU SA sold 1,051 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $56.9K.
Towarzystwo Funduszy Inwestycyjnych PZU SA first reported a position in BioMarin Pharmaceuticals in Q4 2020 and held it in 12 quarters.
Towarzystwo Funduszy Inwestycyjnych PZU SA's BioMarin Pharmaceuticals position peaked at $170K in Q4 2023.
539 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Towarzystwo Funduszy Inwestycyjnych PZU SA's 13F filing for Q4 2025, filed 13 Feb 2026.